Chugai Pharmaceutical
Chugai Pharmaceutical is an R&D-oriented pharmaceutical company with strengths in its unique drug discovery technology platform, including antibody engineering technology.
Launch date
Employees
Market cap
AUD131.6b
Enterprise valuation
AUD121.9b (Public information from Sep 2024)
Share price
JPY6877 4519.T
Tokyo Japan (HQ)
Financials
Estimates*
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 786.9b | 999.8b | 1.3t | 1.1t | 1.1t | 1.2t | 1.2t |
| % growth | 15 % | 27 % | 26 % | (12 %) | 1 % | 3 % | 5 % |
| EBITDA | 298.3b | 419.4b | 531.2b | 443.8b | 531.0b | 538.5b | 570.2b |
| % EBITDA margin | 38 % | 42 % | 42 % | 40 % | 48 % | 47 % | 47 % |
| Profit | 214.7b | 303.0b | 374.4b | 325.5b | 365.5b | 384.0b | 415.6b |
| % profit margin | 27 % | 30 % | 30 % | 29 % | 33 % | 33 % | 34 % |
| EV / revenue | 11.0x | 5.7x | 4.0x | 7.2x | 10.1x | 9.6x | 9.0x |
| EV / EBITDA | 29.1x | 13.5x | 9.5x | 18.1x | 21.2x | 20.6x | 19.1x |
| R&D budget | 117.9b | 137.3b | 149.6b | 174.9b | - | - | - |
| R&D % of revenue | 15 % | 14 % | 12 % | 16 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Chugai Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
